Formation of the Australian and New Zealand Vasculitis Society (ANZVASC) to improve the care of patients with vasculitis in Australia and New Zealand

Ryan, Jessica; Tieu, Joanna; Bose, Bhadran; Francis, Ross; Gingold, Michael; Goh, Liang Kee; Gray, James A.; Hill, Catherine; Hissaria, Pravin; Jahan, Sadia; Langguth, Daman; Li, Jennifer; McLean‐Tooke, Andrew; Peh, Chen Au; Rahman, Mukhlesur; Sammel, Tony; Stamp, Lisa K.; Street, Mark; Swaminathan, Sanjay; Wong, Nikki; Kitching, Richard

doi:10.1111/imj.14898

Cited by 3 publications

(8 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While case series provide an important framework for understanding trends in the diagnosis and treatment of rare diseases such as vasculitis, future coordinated efforts to establish prospective clinical registries will be important for advancing vasculitis research in Australia and New Zealand. 3 …”

Section: Discussionmentioning

confidence: 99%

“…diseases such as vasculitis, future coordinated efforts to establish prospective clinical registries will be important for advancing vasculitis research in Australia and New Zealand. 3 AUTHOR CONTRIBUTIONS Peter T. Bell and Gregory J. Keir designed the study. Peter T. Bell collected the raw data and wrote the first draft of the manuscript.…”

Section: Conflict Of Interestmentioning

confidence: 99%

“…1 Respiratory tract involvement is highly variable, difficult to treat, and often associated with substantial morbidity. 2 A recent Editorial published in the Internal Medicine Journal 3 outlines key challenges in the care of patients with vasculitis in Australia and New Zealand. One such challenge is the paucity of data describing local epidemiology and treatment outcomes, 3 with even fewer detailed accounts of pulmonary manifestations of AAV.…”

Section: Introductionmentioning

confidence: 99%

“…2 A recent Editorial published in the Internal Medicine Journal 3 outlines key challenges in the care of patients with vasculitis in Australia and New Zealand. One such challenge is the paucity of data describing local epidemiology and treatment outcomes, 3 with even fewer detailed accounts of pulmonary manifestations of AAV. Here, we characterize the spectrum of disease manifestations and treatment outcomes in a large single-centre case series of patients with AAV-associated respiratory disease.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Pulmonary involvement in Anti‐Neutrophil Cytoplasmic Antibody Associated Vasculitis: A single centre case series

Bell

Sheehy

Droney

et al. 2022

Respirology Case Reports

View full text Add to dashboard Cite

Anti‐Neutrophil Cytoplasmic Antibody associated Vasculitides (AAV) comprise a rare group of disorders in which respiratory tract involvement is variable and often severe. The rarity and heterogeneity of AAV makes this a challenging condition to diagnose and manage. In this single‐centre case series of 44 patients with AAV‐associated respiratory disease, we provide an overview of disease manifestations, management aspects and treatment outcomes. Data from this case series highlight the real‐world diagnostic and therapeutic challenges of the AAV respiratory disease spectrum; including uncertainties in the management of fibrosing interstitial lung disease, tracheobronchial stenosis and diffuse alveolar haemorrhage.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Conflict Of Interestmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Pulmonary involvement in Anti‐Neutrophil Cytoplasmic Antibody Associated Vasculitis: A single centre case series

Bell

Sheehy

Droney

et al. 2022

Respirology Case Reports

View full text Add to dashboard Cite

show abstract

“…1 As a result of the multi-organ, systemic nature of the disease, in Australia and New Zealand, patients with AAV are managed by a range of specialties, including rheumatology, clinical immunology and nephrology. 2 Currently, in Australia and New Zealand, there is no national AAV registry and, consequently, limited data on the treatment and outcomes of AAV patients. Defining and monitoring variation in clinical care is important in improving patient outcomes and is prioritised by the National Safety and Quality Health Service Standards.…”

Section: Introductionmentioning

confidence: 99%

Variation in approaches to acute ANCA‐associated vasculitis in Australia and New Zealand: rituximab, plasma exchange and glucocorticoids

Chua,

Dentrinos,

Kitching

et al. 2024

Internal Medicine Journal

Self Cite

View full text Add to dashboard Cite

BackgroundAnti‐neutrophil cytoplasmic antibody (ANCA)‐associated vasculitis (AAV) is a rare autoimmune disease which is managed by a range of specialities. There are limited data on treatment practices in Australia and New Zealand.AimsTo understand current patterns of acute AAV treatment in Australia and New Zealand.MethodsAn online survey was conducted between July and October 2022 investigating physicians' views on the management of AAV, focusing on induction therapy. The survey contained questions pertaining to access to treatment and responses to clinical management scenarios. Eosinophilic granulomatosis with polyangiitis was not included. A chi‐squared test of independence was performed for statistical analysis.ResultsFrom a total of 55 responses, plasma exchange was difficult to access for 44% of respondents, more so in rural centres, and they also had difficulty accessing infusion centres. New Zealand clinicians had more difficulty accessing rituximab, with only 44% reporting easy access compared with Australian clinicians (93%). With clinical management scenarios, there was variation in the dosing regimen of glucocorticoids and initiation of plasma exchange, with 42% of respondents prescribing a glucocorticoid regimen different from the standard of care, the ‘reduced‐dose’ arm of the Plasma Exchange and Glucocorticoids for the Treatment of ANCA‐Associated Vasculitis trial. The choice of cyclophosphamide or rituximab for induction therapy was based on patient characteristics and medical history.ConclusionsThere is substantial variation in approaches to the acute management of AAV in Australia and New Zealand, including differences in resource availability. This variation in care demonstrates the need to implement current practice guidelines and institute contemporary monitoring of AAV management, to achieve best patient outcomes.

show abstract

Review of Novel Therapies and Update for Takayasu Arteritis and ANCA-Associated Vasculitis with Relevance to the Asia Pacific Region

Tian

Zeng

2022

Journal of Clinical Rheumatology and Immunology

View full text Add to dashboard Cite

The clinical studies of Takayasu’s arteritis and antineutrophil cytoplasm antibodies (ANCA)-associated vasculitis are very active in the Asia Pacific region. The results of these studies give us a more comprehensive understanding of these vasculitis, which may not only change the management and long-term prognosis of the disease, but also reduce complications and prolonged survival time. Therefore, we summarize the results of these studies that were led or actively participated by investigators in the Asia Pacific region from 2020 to 2021, mainly focusing on the clinical characteristics and management.

show abstract

Formation of the Australian and New Zealand Vasculitis Society (ANZVASC) to improve the care of patients with vasculitis in Australia and New Zealand

Cited by 3 publications

References 22 publications

Pulmonary involvement in Anti‐Neutrophil Cytoplasmic Antibody Associated Vasculitis: A single centre case series

Pulmonary involvement in Anti‐Neutrophil Cytoplasmic Antibody Associated Vasculitis: A single centre case series

Variation in approaches to acute ANCA‐associated vasculitis in Australia and New Zealand: rituximab, plasma exchange and glucocorticoids

Review of Novel Therapies and Update for Takayasu Arteritis and ANCA-Associated Vasculitis with Relevance to the Asia Pacific Region

Contact Info

Product

Resources

About